BioVie Inc. Gain (Loss) on Sale of Derivatives
BioVie Inc. (BIVI) reported Gain (Loss) on Sale of Derivatives of $3.77 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfDerivatives · last filed 2026-08-13
- BioVie Inc. gain (loss) on sale of derivatives for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- BioVie Inc. gain (loss) on sale of derivatives for the quarter ending 2025-03-31 was $7.29K, a 93.31% decline year-over-year.
- BioVie Inc. gain (loss) on sale of derivatives for the quarter ending 2024-12-31 was -$6.04K, a 100.61% decline year-over-year.
- BioVie Inc. gain (loss) on sale of derivatives for the quarter ending 2024-09-30 was $2.52K, a 99.64% decline year-over-year.
- BioVie Inc. gain (loss) on sale of derivatives for fiscal 2025 was $3.77K.
- BioVie Inc. gain (loss) on sale of derivatives for fiscal 2023 was -$1.44M, a 143.73% decline from fiscal 2022.
- BioVie Inc. gain (loss) on sale of derivatives for fiscal 2022 was $3.29M, a 60.30% decline from fiscal 2021.
- BioVie Inc. gain (loss) on sale of derivatives for fiscal 2021 was $8.28M.
| Period end | Gain (Loss) on Sale of Derivatives 3 month | Gain (Loss) on Sale of Derivatives 6 month | Gain (Loss) on Sale of Derivatives 9 month | Gain (Loss) on Sale of Derivatives 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | $7.29K derived: sum of 2 quarters · filed 2026-08-13 | $1.25K derived: sum of 3 quarters · filed 2026-08-13 | $3.77K 10-K · filed 2026-08-13 |
| 2025-03-31 | $7.29K S-1/A · filed 2026-08-06 | $1.25K derived: sum of 2 quarters · filed 2026-08-06 | $3.77K S-1/A · filed 2026-08-06 | $20.70K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$6.04K 10-Q · filed 2026-02-06 | -$3.52K 10-Q · filed 2026-02-06 | $13.41K derived: sum of 3 quarters · filed 2026-08-06 | $122.42K derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-09-30 | $2.52K 10-Q · filed 2025-11-10 | $19.45K derived: sum of 2 quarters · filed 2026-08-06 | $128.45K derived: sum of 3 quarters · filed 2026-08-06 | $1.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-06-30 | $16.93K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | $125.94K derived: sum of 2 quarters · filed 2026-08-06 | $1.11M derived: sum of 3 quarters · filed 2026-08-06 | $1.82M S-1/A · filed 2026-08-06 |
| 2024-03-31 | $109.00K 10-Q · filed 2025-05-12 | $1.09M derived: sum of 2 quarters · filed 2025-05-12 | $1.80M 10-Q · filed 2025-05-12 | $4.52M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $982.53K 10-Q · filed 2025-02-11 | $1.69M 10-Q · filed 2025-02-11 | $4.41M derived: sum of 3 quarters · filed 2025-02-11 | $4.04M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-09-30 | $707.80K 10-Q · filed 2024-11-13 | $3.42M derived: sum of 2 quarters · filed 2024-11-13 | $3.06M derived: sum of 3 quarters · filed 2024-11-13 | -$163.14K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $2.35M derived: sum of 2 quarters · filed 2024-09-30 | -$870.94K derived: sum of 3 quarters · filed 2024-09-30 | -$1.44M 10-K · filed 2024-09-30 |
| 2023-03-31 | -$366.09K 10-Q · filed 2024-05-14 | -$3.59M derived: sum of 2 quarters · filed 2024-05-14 | -$4.15M 10-Q · filed 2024-05-14 | -$2.04M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$3.22M 10-Q · filed 2024-02-13 | -$3.79M 10-Q · filed 2024-02-13 | -$1.67M derived: sum of 3 quarters · filed 2024-02-13 | -$2.06M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$566.54K 10-Q · filed 2023-11-08 | $1.55M derived: sum of 2 quarters · filed 2023-11-08 | $1.17M derived: sum of 3 quarters · filed 2023-11-08 | $2.72M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16 | $1.73M derived: sum of 2 quarters · filed 2023-08-16 | $3.29M derived: sum of 3 quarters · filed 2023-08-16 | $3.29M 10-K · filed 2023-08-16 |
| 2022-03-31 | -$386.45K 10-Q · filed 2023-05-12 | $1.17M derived: sum of 2 quarters · filed 2023-05-12 | $1.17M 10-Q · filed 2023-05-12 | |
| 2021-12-31 | $1.56M 10-Q · filed 2023-02-10 | $1.56M 10-Q · filed 2023-02-10 | ||
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $0.00 derived: sum of 2 quarters · filed 2022-09-27 | $0.00 derived: sum of 3 quarters · filed 2022-09-27 | $8.28M 10-K · filed 2022-09-27 |
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-05-11 | $8.28M 10-Q · filed 2022-05-11 | -$9.06M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-08 | $8.28M 10-Q · filed 2022-02-08 | -$9.06M derived: sum of 3 quarters · filed 2022-02-08 | -$8.69M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-09-30 | $8.28M 10-Q · filed 2021-11-10 | -$9.06M derived: sum of 2 quarters · filed 2021-11-10 | -$8.69M derived: sum of 3 quarters · filed 2021-11-10 | -$1.29M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$17.34M derived: 10-K 12 month − 10-Q 9 month · filed 2021-08-30 | -$16.97M derived: sum of 2 quarters · filed 2021-08-30 | -$9.57M derived: sum of 3 quarters · filed 2021-08-30 | -$9.21M 10-K · filed 2021-08-30 |
| 2020-03-31 | $366.55K 10-Q · filed 2021-05-10 | $7.76M derived: sum of 2 quarters · filed 2021-05-10 | $8.13M 10-Q · filed 2021-05-10 | |
| 2019-12-31 | $7.40M 10-Q · filed 2021-01-29 | $7.76M 10-Q · filed 2021-01-29 | ||
| 2019-09-30 | $362.59K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |